19-Feb-2026
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Day One Biopharmaceuticals (DAWN)
TipRanks (Mon, 16-Feb 4:00 AM ET)
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
Globe Newswire (Tue, 10-Feb 8:30 AM ET)
Market Chameleon (Mon, 12-Jan 2:06 AM ET)
Globe Newswire (Sun, 11-Jan 5:00 PM ET)
Day One Completes Acquisition of Mersana Therapeutics
Globe Newswire (Tue, 6-Jan 9:02 AM ET)
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 16-Dec 8:30 AM ET)
Globe Newswire (Mon, 24-Nov 8:00 AM ET)
Day One’s Mersana Acquisition Puts Fast-Track Oncology Candidate Emi-Le in the Spotlight
Market Chameleon (Thu, 13-Nov 2:36 AM ET)
Market Chameleon (Wed, 5-Nov 6:25 AM ET)
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
Day One Biopharmaceuticals trades on the NASDAQ stock market under the symbol DAWN.
As of February 19, 2026, DAWN stock price climbed to $12.07 with 1,234,571 million shares trading.
DAWN has a beta of 1.10, meaning it tends to be more sensitive to market movements. DAWN has a correlation of 0.07 to the broad based SPY ETF.
DAWN has a market cap of $1.24 billion. This is considered a Small Cap stock.
Last quarter Day One Biopharmaceuticals reported $40 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.09.
In the last 3 years, DAWN traded as high as $20.39 and as low as $5.64.
The top ETF exchange traded funds that DAWN belongs to (by Net Assets): XBI, VTI, IWM, VB, VXF.
DAWN has underperformed the market in the last year with a return of +1.2%, while SPY returned +13.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DAWN shares. However, DAWN has outperformed the market in the last 3 month and 2 week periods, returning +40.8% and +12.4%, while SPY returned +4.0% and -0.2%, respectively. This indicates DAWN has been having a stronger performance recently.
DAWN support price is $11.05 and resistance is $12.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DAWN shares will trade within this expected range on the day.